Nuvation Bio Inc.

Nuvation Bio Inc. (Nasdaq: NUVB) is a clinical-stage biopharmaceutical company focused on oncology that became publicly traded through a business combination with Panacea Acquisition Corp. II, a blank-check vehicle that completed its initial public offering in 2021 under sponsor Panacea Acquisition Management, LLC. Nuvation Bio develops novel therapeutic candidates targeting cancer and operates as a fully reporting public company following the de-SPAC merger, which closed in early 2022. The company submitted a Form 8-K with the SEC on May 27, 2026, representing its most recent regulatory disclosure on record. Sign up at SpacDesk for complete filing history, sponsor intelligence, and deal analytics on NUVB and hundreds of other SPAC transactions.